Genmab — Maj 2018

[E_L]

GMXAY bid-offer is 20.05-20.99 at the moment (or in dkk 1249-1308); that is almost 5%... useless...

[peter12]

But yesterday someone actually bought ~131 shares for 171479,- soo...;-)

[pauly]

down 4%

[pauly]

(finance.yahoo.com)

[peter12]

I går var der 16 handler. I dag een ? Det er nemt at manipulere GMXAY

[Bulder]

Så vidt jeg kan se er der kun 2 konkrete ting fra Trump. 1: skærpelse af konkurrencen og 2: At rabatter deles med patienterne, således at deres egenbetaling mindskes. Ikke så mærkeligt, at NBI ser ud til at ånde lettet op.

[Solsen]

Nissen må have sagt noget godt for pharma

[Solsen]

Du kom først

[pauly]

det er fart på nbi

[pauly]

I kom først

[bikube]

GMXAY ligger i 20,99 = 1316,30 kr.

[E_L]

if NBI / IBB will guide for Monday; they are trading +-4% above where it was Wednesday 5pm when genmab closed , inidicating the rollercoaster can go back to 1300. We'll see lol

[E_L]

EP Vantage http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=787058&isEPVantage=yes

[hspinvest]

Så lukker SEB 4*bull GENMAB - banditter i habitter......

[Weatherman]

Sjovt nok umiddelbart efter SEB opjusterede kursmålet med 10 procent. Men det er nok bare et tilfælde....

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

MS partner Novartis showing its strength again there with another approval https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-gilenyar-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis

[E_L]

this "Short Course Daratumumab " already started recruiting https://clinicaltrials.gov/ct2/history/NCT03490344?A=1&B=2&C=merged

[E_L]

Janssen changing the design of this Prostate cancer trial, adding a second arm with "JNJ-40346527 " https://clinicaltrials.gov/ct2/history/NCT03177460?A=6&B=7&C=merged

[peter12]

Its also mentioned here ? https://www.mdanderson.org/publications/oncolog/january-2018/immunotherapy-for-genitourinary-cancers.html